David A. Siegel Virios Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.31 - $4.89 $47,664 - $70,416	-14,400 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.48 - $6.92 $448 - $692	-100 Reduced 0.69%	14,400 $65,000
Q4 2021 Feb 14, 2022	SELL	$4.07 - $6.12 $56,573 - $85,068	-13,900 Reduced 48.94%	14,500 $74,000
Q3 2021 Nov 15, 2021	BUY	$4.61 - $6.56 $17,057 - $24,272	3,700 Added 14.98%	28,400 $150,000
Q2 2021 Aug 16, 2021	SELL	$4.71 - $6.95 $58,404 - $86,180	-12,400 Reduced 33.42%	24,700 $155,000
Q1 2021 May 17, 2021	BUY	$5.01 - $8.84 $185,871 - $327,964	37,100 New	37,100 $213,000

1.12M

Ticker VIRI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,330,400
Market Cap $81.4M
Description
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.